Intest Res.  2022 Jul;20(3):386-388. 10.5217/ir.2020.00172.

Update on SARS-CoV-2 vaccination of patients with inflammatory bowel disease: what clinicians need to know

• Lee YJ
• Kim SE
• Park YE
• Chang JY
• Song HJ
• Kim DH
• Yang YJ
• Kim BC
• Lee JG
• Yang HC
• Myung SJ
• Clinical Practice Guideline Committee of the Korean Association for the Study of Intestinal Diseases

• KMID: 2531993
• DOI: http://doi.org/10.5217/ir.2020.00172

Reference

1. Kim KO, Jang BI. Management of inflammatory bowel disease in the COVID-19 era. Intest Res. 2022; 20:3–10.

2. Park YE, Lee YJ, Chang JY, et al. Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements. Intest Res. 2022; Jan. 5. [Epub]. https://doi.org/10.5217/ir.2021.00111.

3. Lee YJ, Kim SE, Park YE, et al. SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID. Intest Res. 2022; 20:171–183.

4. Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2022; 21:102927.

5. Lin S, Kennedy NA, Saifuddin A, et al. Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients. Res Sq. [Preprint]. 2021 [cited 2021 Dec 18]. https://doi.org/10.21203/rs.3.rs-755879/v1.

6. Khan N, Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology. 2021; 161:827–836.

7. Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021; 70:1884–1893.

8. The Joint Committee on Vaccination and Immunisation. Joint Committee on Vaccination and Immunisation (JCVI) advice on third primary dose vaccination [Internet]. c2021 [cited 2021 Dec 18]. https://www.gov.uk/government/publications/third-primary-covid-19-vaccine-dose-for-people-who-are-immunosuppressed-jcvi-advice/joint-committee-on-vaccination-and-immunisation-jcvi-advice-on-third-primary-dose-vaccination.

9. Korea Disease Control and Prevention Agency. Revision of COVID-19 vaccination practice standards and related FAQs [Internet]. c2021 [cited 2021 Dec 18]. https://ncv.kdca.go.kr/upload_comm/syview/doc.html?fn=163971744146000.hwp&rs=/upload_comm/docu/0031/.

10. Korea Disease Control and Prevention Agency. Additional vaccination for immunocompromised and underlying disease patients [Internet]. c2021 [cited 2021 Dec 18]. https://ncv.kdca.go.kr/board.es?mid=a12105000000&bid=0035&act=view&list_no=628.

11. Li D, Debbas P, Cheng S, Braun J, McGovern DP, Melmed GY. Post-vaccination symptoms after a third dose of mRNA SARS-CoV-2 vaccination in patients with inflammatory bowel disease. medRxiv. [Preprint]. 2021 [cited 2021 Dec 18]. https://doi.org/10.1101/2021.12.05.21266089.

12. Kasehagen L, Byers P, Taylor K, et al. COVID-19-associated deaths after SARS-CoV-2 infection during pregnancy: Mississippi, March 1, 2020-October 6, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70:1646–1648.